title: Propeptide of type I procollagen is predictive of posttreatment bone mass gain in adult celiac disease.
abstract: OBJECTIVE
  Adult celiac disease is associated with osteopenia, which is not always reversible after gluten-free diet (GFD). A prospective study was conducted to evaluate whether pretreatment indices of bone and mineral metabolism are predictive of the extent of bone mass gain after diet.
  
  
  METHODS
  Lumbar and femoral bone mineral density (z-score) and serum levels of parathyroid hormone, 1,25-dihydroxycholecalciferol, COOH-terminal propeptide of type I procollagen (PICP), and COOH-terminal telopeptide of type I collagen (ICTP) were measured in 20 celiac patients at diagnosis and after 2 years of GFD.
  
  
  RESULTS
  All patients showed a posttreatment improvement in bone mass and in serum levels of indices of bone and mineral metabolism. Nevertheless, only in 12 of 20 patients was this improvement at least equal to half the SD of the z-score, which equals a gain of at least 5% in bone mass. Pretreatment levels of PICP strictly correlated with the increase in lumbar (r(s) = 0.92; P < 0.001) and femoral z-scores (r(s) = 0.89; P < 0.001). Only in patients with basal PICP above the normal range did the z-score increase after GFD by at least half the SD.
  
  
  CONCLUSIONS
  In adult celiac disease, a high rate of osteosynthetic activity before treatment is predictive of the satisfactory recovery of bone mass after GFD.
authors.affiliation: Department of Internal Medicine, University of L'Aquila, Italy.
authors.forename: G R
authors.initials: GR
authors.lastname: Corazza
authors.forename: M
authors.initials: M
authors.lastname: Di Stefano
authors.forename: R A
authors.initials: RA
authors.lastname: Jorizzo
authors.forename: L
authors.initials: L
authors.lastname: Cecchetti
authors.forename: L
authors.initials: L
authors.lastname: Minguzzi
authors.forename: G
authors.initials: G
authors.lastname: Gasbarrini
mesh_terms: D015502:Absorptiometry, Photon; D000328:Adult; D015519:Bone Density; D001851:Bone Diseases, Metabolic / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control; D002117:Calcitriol / Q000097:blood; D002118:Calcium / Q000097:blood; D016022:Case-Control Studies; D002446:Celiac Disease / Q000150:complications / Q000178:diet therapy*; D003094:Collagen / Q000097:blood; D024042:Collagen Type I; D005260:Female; D005269:Femur / Q000000981:diagnostic imaging; D005983:Glutens / Q000008:administration & dosage; D006801:Humans; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging; D008297:Male; D010281:Parathyroid Hormone / Q000097:blood; D010446:Peptide Fragments / Q000097:blood*; D010455:Peptides / Q000097:blood; D011237:Predictive Value of Tests; D011347:Procollagen / Q000097:blood*; D011446:Prospective Studies
chemical_list: D024042:Collagen Type I; D010281:Parathyroid Hormone; D010446:Peptide Fragments; D010455:Peptides; D011347:Procollagen; C052929:collagen type I trimeric cross-linked peptide; C042813:procollagen type I carboxy terminal peptide; D005983:Glutens; D003094:Collagen; D002117:Calcitriol; D002118:Calcium